University of Iowa HCCC Presents Prelim Data from Trial of Vidutolimod
26 May 2022 //
GLOBENEWSWIRE
Checkmate details troubled future if Regeneron deal fails
14 May 2022 //
FIERCEBIOTECH
A promising cancer drug leads Regeneron to reconsider its aversion to M&A
20 Apr 2022 //
BIOPHARMADIVE
Checkmate Pharma Presents Trial Biomarker Data with Vidutolimod at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Checkmate Presents Data for Phase 1b Study Evaluating Vidutolimod at SITC
12 Nov 2021 //
GLOBENEWSWIRE